Closed · RFA-DK-26-313 · CFDA 93.847 · Discretionary
Single Source for Continuation of the Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal (U01 Research Project (Cooperative Agreement) Clinical Trial not allowed)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $2M
- Award range
- Closed
- Status
- March 10, 2026
- Close date
- 1
- Expected awards
The verdict
Single Source for Continuation of the Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal (U01 Research Project (Cooperative Agreement) Clinical Trial not allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $2,000,000 across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $2M
- award range
- Closed
- application status
- 1
- expected award
- 93.847
- CFDA program
Recently closed NOFO
This listing closed on March 10, 2026. Watch CFDA 93.847 (Diabetes, Endocrine, and Metabolic Disease Research) for the next funding cycle. Historical award band was Up to $2,000,000.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed March 10, 2026
Expected Awards
1
Instrument
Cooperative Agreement
Description
This non-competitive Notice of Funding Opportunity (NOFO) is intended to fund a single award to the current awardee institution of the Accelerating Medicines Partnership in Common Metabolic Diseases Knowledge Portal (AMP CMD KP), the Broad Institute, Inc. The AMP CMD program is a collaborative partnership between the NIH, pharmaceutical companies, and nonprofit organizations to develop new models for identifying and validating promising biological targets to serve as biomarkers and/or for drug discovery (www.nih.gov/research-training/accelerating-medicines-partnership-amp/type-2-diabetes). This is a one-time NOFO to provide funds to the AMP CMD KP to continue the development and maintenance of the web portal and underlying, curated knowledge base; which serves as the flagship resource encompassing the myriad types of data and information that provide an understanding of the biological heterogeneity in patients with CMDs and their related complications. In its next five-year period, the AMP CMD KP will be expected to continue its expansion of its datasets and traits, import additional data types, deploy additional analytical and visualization tools, and increase its utility to a more diverse user base, and to develop a framework for independent sustainability. The application will be peer-reviewed and if it is not a meritorious application, it will not be funded.
Catch-all / unrestricted eligibility mark · RFA-DK-26-313
Grants.gov marks Single Source for Continuation of the Acceler… with a catch-all / unrestricted eligibility code (Others (see official listing text)). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity code maps to Health (HL). Only 187 other National Institutes of Health listings share this exact eligibility-code string (2% of 12,420).
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Diabetes, Endocrine, and Metabolic Disease Research
National Institutes of Health
Agency Contact
Division of Diabetes, Endocrinology and Metabolic Diseases NIDDK_DEM@nih.gov
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Single Source for Continuation of the Acceler… is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.847 may publish future NOFOs under the same assistance listing. Open program
- Diabetes, Endocrine, and Metabolic Disease Re… indexes 72 Grants.gov listings in this extract. Program profile
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |